2nd Annual Nonalcoholic Steatohepatitis (NASH) Summit
Event Date: April 23 - 25, 2018
Event Location: Revere Hotel Boston, 200 Stuart Street, Boston, MA, 02116
Diapharma is planning to attend the 2nd Annual Nonalcoholic Steatohepatitis (NASH) Summit this year. Please click here to schedule a meeting with us or email us directly.
About The Annual NASH Summit
The 2nd Annual NASH Summit will include drug developers and organizations in a forum to focus on late stage clinical development of non-alcoholic steatohepatitis (NASH) candidates.
The NASH Summit will present data and lessons learned that will enable you to:
- Understand how to progress your candidate towards a combinational NASH treatment
- Define clinical primary and secondary endpoints and understand the status of the biopsy at the time current NASH candidates will enter market to map out your clinical trials
- Utilize metabolomic and inflammatory biomarkers in NASH preclinical development models to more robustly diagnose and track NASH disease progression
- Improve drug efficacy in both early and late stage NASH by identifying and validating novel targets & drug mechanisms of action
The NASH summit’s agenda will include:
- Latest Advancements in NASH Drug Development
- Early stage clinical compounds being evaluated for NASH
- Regulatory guidance on development of NASH therapeutics
- Latest Regulatory Requirements for Developing NASH Therapeutics
- Developing animal models with relevant NASH biology
- Characterization of NASH animal models
- Steatosis and inflammation, fibrosis, markers of stellate cells, as well as serum biomarkers
- Novel Animal Models & Combination Therapies to Combat NASH
- 2 new diet-induced NASH models in mice
- Novel preclinical findings on NASH-reducing capabilities of combining FXR and GLP-1R agonists
- Fructose Metabolism for NASH – KHK Inhibitor
- Treatment with a KHK-inhibitor reverses metabolic dysfunction in several rodent models of NAFLD-NASH
- Critical pathophysiologic drivers of NASH
- Novel targets for NASH and metabolic rare diseases using an in vitro platform
- Targeting Pyruvate Metabolism to Treat NASH
- Difficulties in Effectively Utilizing Available Patients in NASH Clinical Trials
- Genetics in defining NASH pathology from fatty liver to cirrhosis
- Metabolic drivers of NASH and metabolomic identification of NASH patient subtypes
- Fibrosis resulting from other pathologies as a substitute for NASH fibrosis during drug development
- Diabetes and cardiovasular patients as candidate for NASH clinical trials
- Drug Repurposing Strategies in NASH Clinical Trials
- Thyroid hormone receptor beta agonist in the NASH liver reduces lipotoxicity through multiple pathways
- Risk Mitigation of Drug Induced Liver Injury in NASH Drug Development
- Next Generation NASH Therapeutics
- NASH Pathology
- Genes Modulating Risk for NASH Development
- Human Gluco & Liporegulatory Physiology & Pathophysiology as Drivers of Novel NASH Therapies
- Human physiological and pathophysiological basis of commonalities and differences in NASH and related metabolic diseases
- Diabetes therapies to treat NASH and where to seek additional pharmacology
- New NASH serum biomarkers
- Cyp 7b1 as a new target for drug development to combat NAFLD
- Oxysterol metabolites to NASH and insulin resistance
- New Technologies to Identify & Validate Novel Targets in NASH
- Oxidative stress as an important factor in the transition from NAFLD to NASH
- Key enzymes believed to be responsible for oxidative stress in NASH
- Noninvasive diagnostic markers is necessary to effectively track and treat NASH.
- 3D bioprinted human tissues to model liver diseases such as NASH and fibrosis
- Serum and imaging biomarkers as traceable representatives of NASH pathology
- Combinational Therapies in the Treatment of NASH
- Liver injury in NASH
- Immunological & Molecular Pathways of NASH Pathology
- MetAP2 Inhibitors in the Treatment of NASH
- Bile acid receptors to treat NASH
- TGR5 and FXR agonists approaches to NASH
- Inflammation in NASH driven fibrosis
- Signaling pathways and miRNA biomarkers in NASH
- Relationship of NASH with Other Diseases
- Clinical Trials & Endpoints in NASH Cirrhosis
- Pre-cirrhotic and cirrhotic NASH including pathphysiology, clinical complications, progression, and prognosis
- Regulatory endpoints in NASH cirrhosis clinical trials
- NASH Heterogeneity & Relationships as a Sequel of CVM Disease
- NASH & Diabetes Preclinical Animal Models
- Preclinical pharmacology results in diabetes and NASH animal models
- Novel biologics for the treatment of diabetes and NASH
- Metabolic Syndrome as a Driver of NAFLD & NASH
- Preclinical and clinical evidence of entero-hepatic targeting as a therapeutic intervention for NASH
- Cardiometabolic implications in NASH treatment goals
- Preclinical Biomarker Developments in NASH for Better Translation into the Clinic
- Molecular MR Imaging of Oxidized Collagen to Monitor Active Fibrogenesis in Preclinical Models of NASH
- Molecular MR imaging of oxidized collagen decreases after anti-fibrotic treatment in preclinical models of NASH
- Increasing public understanding and appreciation of relevance, scope and impact of NASH
- Improving physician education and appreciation of NASH diagnosis and management from primary care through specialists
- Retrospective data analysis to design and optimize NAFLD/NASH study inclusion criteria
- FGF21 Pathway in NASH
- GLP1 Agonists for the Treatment of NASH
Pre-Conference workshops
Discovery Stream – Workshop A
- Comprehensively Evaluate the Predictions & Understanding of the Microbiome in Nonalcoholic Steatohepatitis.
- Reviewing Preclinical Models In-Depth as a Comparison of Traditional & Next Generation Advantages & Disadvantages
- Reviewing Preclinical Models In-Depth as a Comparison of Traditional & Next Generation Advantages & Disadvantages
Discovery Stream – Workshop B
- Enhance the Understanding of Liver Cell-to-Cell Interactions in the Pathogenesis of NASH & Evaluate the Opportunity for Next Generation Therapeutic Targets
- Exploring the Translatability of Non-Invasive Biomarkers in NASH
- Overcoming NASH as the Next Big Global Epidemic & Evaluating the Challenges of Bringing a NASH Drug to Market